BioCentury
ARTICLE | Company News

Henry Ford Health System other research news

December 22, 1997 8:00 AM UTC

Henry Ford researchers published a meta-analysis of 10 trials comparing angioplasty and thrombolytic therapy (including streptokinase and both normal and accelerated administration of tissue plasminogen activators). As published in the Journal of the American Medical Association, a total of 2606 patients were involved in the trials, which demonstrated a significant benefit of angioplasty over thrombolytics with respect to mortality, death or reinfarction, and stroke.

The rate of death at 30 days was reduced from 6.5 percent in 1316 thrombolytic-treated patients to 4.4 percent in 1290 angioplasty patients (a 34 percent change, p=0.02). The rates for death or reinfarction were 7.2 percent for angioplasty and 11.9 percent for thrombolytics (p<0.001). Angioplasty also led to a significant reduction in both total stroke (0.7 percent versus 2 percent, p=0.007) and hemorrhagic stroke (0.1 percent versus 1.1 percent, p<0.001). ...